Antonio M GottoJr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio M GottoJr has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Henry J. Pownall
Center for Bioenergetics, Department of Medicine, Houston Methodist Research Institute, Houston, TX, USA; Weill Cornell Medicine, 1300 York Avenue, New York, NY
10 shared publications - Baiba Kurins Gillard
Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA
9 shared publications - Corina Rosales
Center for Bioenergetics, Houston Methodist, 6565 Fannin Street, Houston TX 77030, USA; Department of Medicine, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA
7 shared publications - Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
4 shared publications - Alberico Luigi Catapano
Department of Pharmacological and Biomolecular Sciences Università degli Studi di Milano Milan Italy
3 shared publications Dedipya Yelamanchili
Department of Medicine, Houston Methodist, Houston, TX, USA
3 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8317
Features of Lipid Disorders in Cardiovascular–Kidney–Metabolic Syndrome
Cardiovascular–kidney–metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced high-density lipoprotein-cholesterol (HDL-C), increased apolipoprotein B (apoB)-containing lipoproteins, remnant cholesterol (RC) accumulation, small dense low-density lipoprotein (LDL) particles, and frequently elevated lipoprotein(a) [Lp(a)]. Such lipid abnormalities contribute to accelerated atherosclerosis and early renal deterioration. In turn, kidney dysfunction further amplifies lipid abnormalities. These pathways underscore the need for a timely and comprehensive lipid assessment using apoB, non-HDL-C, RC, and Lp(a) within the CKM framework. Effective lipid management is crucial for CKM syndrome treatment, with the potential to reduce residual cardiovascular and renal risk and improve long-term clinical outcomes. In this narrative review, we examine current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia and provide a practical framework for its assessment and management. Management requires a multimodal approach tailored to the patient’s lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection.
- 18 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8317
Open AccessFeatures of Lipid Disorders in Cardiovascular–Kidney–Metabolic Syndrome
Cardiovascular–kidney–metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced high-density lipoprotein-cholesterol (HDL-C), increased apolipoprotein B (apoB)-containing lipoproteins, remnant cholesterol (RC) accumulation, small dense low-density lipoprotein (LDL) particles, and frequently elevated lipoprotein(a) [Lp(a)]. Such lipid abnormalities contribute to accelerated atherosclerosis and early renal deterioration. In turn, kidney dysfunction further amplifies lipid abnormalities. These pathways underscore the need for a timely and comprehensive lipid assessment using apoB, non-HDL-C, RC, and Lp(a) within the CKM framework. Effective lipid management is crucial for CKM syndrome treatment, with the potential to reduce residual cardiovascular and renal risk and improve long-term clinical outcomes. In this narrative review, we examine current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia and provide a practical framework for its assessment and management. Management requires a multimodal approach tailored to the patient’s lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection.
- Open Access
- 24 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1649759
LDL atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review
Atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease and cerebrovascular disease, is caused by the accumulation of plaque on artery walls. Elevated levels of low-density lipoprotein (LDL) cholesterol significantly contribute to the development and progression of ASCVD. Multiple studies have provided evidence of a correlation between individual LDL subpopulations and the development of atherosclerosis (AS); among these, small, dense low-density lipoprotein (sdLDL) and lipoprotein(a) [Lp(a)] have been particularly implicated. There are multiple considerations of why sdLDL may cause AS including their low affinity for the LDL receptor, their ability to diffuse into the artery wall and remain there for a long time, and their tendency to become excessively oxidized. Oxidized LDL (oxLDL), generated under oxidative stress, drives AS by impairing endothelial function, promoting foam cell formation, and triggering vascular inflammation. Lp(a) contributes to the development and progression of AS by causing inflammation of the arterial wall. Studies conducted in recent years have found that electronegative LDL [L5/LDL(-)] may also be an important factor in the development and progression of AS. L5/LDL(-) causes atherosclerotic changes in the vascular wall by triggering apoptosis in endothelial cells via the lectin-like oxLDL receptor-1. This article offers an updated overview of ASCVD and briefly examines the classifications of atherogenic LDL subfractions and their roles in atherogenesis.
- 24 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1649759
Open AccessLDL atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review
Atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease and cerebrovascular disease, is caused by the accumulation of plaque on artery walls. Elevated levels of low-density lipoprotein (LDL) cholesterol significantly contribute to the development and progression of ASCVD. Multiple studies have provided evidence of a correlation between individual LDL subpopulations and the development of atherosclerosis (AS); among these, small, dense low-density lipoprotein (sdLDL) and lipoprotein(a) [Lp(a)] have been particularly implicated. There are multiple considerations of why sdLDL may cause AS including their low affinity for the LDL receptor, their ability to diffuse into the artery wall and remain there for a long time, and their tendency to become excessively oxidized. Oxidized LDL (oxLDL), generated under oxidative stress, drives AS by impairing endothelial function, promoting foam cell formation, and triggering vascular inflammation. Lp(a) contributes to the development and progression of AS by causing inflammation of the arterial wall. Studies conducted in recent years have found that electronegative LDL [L5/LDL(-)] may also be an important factor in the development and progression of AS. L5/LDL(-) causes atherosclerotic changes in the vascular wall by triggering apoptosis in endothelial cells via the lectin-like oxLDL receptor-1. This article offers an updated overview of ASCVD and briefly examines the classifications of atherogenic LDL subfractions and their roles in atherogenesis.
- Open Access
- 17 July 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (4) , 1107-1129
Atherosclerosis features in patients with heart failure
Heart failure (HF) and atherosclerosis represent two major cardiovascular diseases that are intricately linked, both contributing significantly to global morbidity, mortality, and healthcare burden. Despite substantial progress in diagnostic methods and therapeutic strategies, the overall impact of these conditions remains considerable. This is largely due to their complex and overlapping pathophysiological mechanisms, persistent residual atherosclerotic risk, and the ongoing challenges associated with implementing guideline-directed medical therapy for HF in routine clinical practice. Recent advancements in the management of diverse HF phenotypes, lipid abnormalities, atherosclerotic cardiovascular disease (ASCVD), and obesity have facilitated the adoption of multidrug regimens. These include beta-blockers, renin-angiotensin-aldosterone system inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1), which have collectively improved outcomes in HF populations. This review aims to elucidate the shared pathophysiological mechanisms linking these conditions and to examine their clinical overlap with ischemic heart disease, cerebrovascular disease, peripheral arterial disease, dyslipidemia, and obesity.
- 17 July 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (4) , 1107-1129
Open AccessAtherosclerosis features in patients with heart failure
Heart failure (HF) and atherosclerosis represent two major cardiovascular diseases that are intricately linked, both contributing significantly to global morbidity, mortality, and healthcare burden. Despite substantial progress in diagnostic methods and therapeutic strategies, the overall impact of these conditions remains considerable. This is largely due to their complex and overlapping pathophysiological mechanisms, persistent residual atherosclerotic risk, and the ongoing challenges associated with implementing guideline-directed medical therapy for HF in routine clinical practice. Recent advancements in the management of diverse HF phenotypes, lipid abnormalities, atherosclerotic cardiovascular disease (ASCVD), and obesity have facilitated the adoption of multidrug regimens. These include beta-blockers, renin-angiotensin-aldosterone system inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1), which have collectively improved outcomes in HF populations. This review aims to elucidate the shared pathophysiological mechanisms linking these conditions and to examine their clinical overlap with ischemic heart disease, cerebrovascular disease, peripheral arterial disease, dyslipidemia, and obesity.
- Open Access
- 19 November 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 66 (1) , 100707
HDL-free cholesterol influx into macrophages and transfer to LDL correlate with HDL-free cholesterol content
- 19 November 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 66 (1) , 100707
Open AccessHDL-free cholesterol influx into macrophages and transfer to LDL correlate with HDL-free cholesterol content
- 14 September 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (6) , e879-e881
Akira Endo (1933–2024), in memoriam
- 14 September 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (6) , e879-e881
Akira Endo (1933–2024), in memoriam
- Open Access
- 16 May 2024
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 26 (7) , 317-329
Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease
Purpose of Review: Low-density lipoprotein (LDL) poses a risk for atherosclerotic cardiovascular disease (ASCVD). As LDL comprises various subtypes differing in charge, density, and size, understanding their specific impact on ASCVD is crucial. Two highly atherogenic LDL subtypes—electronegative LDL (L5) and Lp(a)—induce vascular cell apoptosis and atherosclerotic changes independent of plasma cholesterol levels, and their mechanisms warrant further investigation. Here, we have compared the roles of L5 and Lp(a) in the development of ASCVD. Recent Findings: Lp(a) tends to accumulate in artery walls, promoting plaque formation and potentially triggering atherosclerosis progression through prothrombotic or antifibrinolytic effects. High Lp(a) levels correlate with calcific aortic stenosis and atherothrombosis risk. L5 can induce endothelial cell apoptosis and increase vascular permeability, inflammation, and atherogenesis, playing a key role in initiating atherosclerosis. Elevated L5 levels in certain high-risk populations may serve as a distinctive predictor of ASCVD. Summary: L5 and Lp(a) are both atherogenic lipoproteins contributing to ASCVD through distinct mechanisms. Lp(a) has garnered attention, but equal consideration should be given to L5.
- 16 May 2024
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 26 (7) , 317-329
Open AccessComparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease
Purpose of Review: Low-density lipoprotein (LDL) poses a risk for atherosclerotic cardiovascular disease (ASCVD). As LDL comprises various subtypes differing in charge, density, and size, understanding their specific impact on ASCVD is crucial. Two highly atherogenic LDL subtypes—electronegative LDL (L5) and Lp(a)—induce vascular cell apoptosis and atherosclerotic changes independent of plasma cholesterol levels, and their mechanisms warrant further investigation. Here, we have compared the roles of L5 and Lp(a) in the development of ASCVD. Recent Findings: Lp(a) tends to accumulate in artery walls, promoting plaque formation and potentially triggering atherosclerosis progression through prothrombotic or antifibrinolytic effects. High Lp(a) levels correlate with calcific aortic stenosis and atherothrombosis risk. L5 can induce endothelial cell apoptosis and increase vascular permeability, inflammation, and atherogenesis, playing a key role in initiating atherosclerosis. Elevated L5 levels in certain high-risk populations may serve as a distinctive predictor of ASCVD. Summary: L5 and Lp(a) are both atherogenic lipoproteins contributing to ASCVD through distinct mechanisms. Lp(a) has garnered attention, but equal consideration should be given to L5.
- Open Access
- 10 October 2023
- Published by Elsevier in Journal of Lipid Research
- Vol. 64 (11) , 100456
Serum opacity factor normalizes erythrocyte morphology in Scarb1−/− mice in an HDL-free cholesterol-dependent way
- 10 October 2023
- Published by Elsevier in Journal of Lipid Research
- Vol. 64 (11) , 100456
Open AccessSerum opacity factor normalizes erythrocyte morphology in Scarb1−/− mice in an HDL-free cholesterol-dependent way
- Open Access
- 31 December 2022
- Published by Elsevier in Journal of Lipid Research
- Vol. 64 (2) , 100327
Serum opacity factor rescues fertility among female Scarb1−/− mice by reducing HDL-free cholesterol bioavailability
- 31 December 2022
- Published by Elsevier in Journal of Lipid Research
- Vol. 64 (2) , 100327
Open AccessSerum opacity factor rescues fertility among female Scarb1−/− mice by reducing HDL-free cholesterol bioavailability
- Open Access
- 13 March 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 16 (3) , 286-297
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
- 13 March 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 16 (3) , 286-297
Open AccessEfficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
- 12 March 2022
- Published by Elsevier in Atherosclerosis
- Vol. 346, 75-76
Professor Jeremiah Stamler (1919–2022), “Father of Preventive Cardiology”
- 12 March 2022
- Published by Elsevier in Atherosclerosis
- Vol. 346, 75-76
Professor Jeremiah Stamler (1919–2022), “Father of Preventive Cardiology”